Acknowledgments This work was supported in part by co-funding from the National Breast Cancer Foundation and Cancer Australia 543400 (K. Sherman), NIH grants R01 CA104979, R01 CA158019, RO1 HG01766, ACS TURSG 02-227, the Fox Chase Cancer Center Behavioral Raf inhibitor Research Core Facility P30 CA06927, Department of Defense grant DAMD 17-01-01-1-0238 (S. Miller), and the Komen Foundation grant POP00-000657 and “Women at Risk” (now) within New York-Presbyterian Hospital/Columbia University Medical Center (S. Sheinfeld Gorin). Conflict of interest Kerry Sherman, Suzanne Miller, Laura-Kate Shaw, Karen Cavanagh, and Sherri Sheinfeld Gorin declare that they have no conflict of interest. Compliance with ethical guidelines
This article does not contain
any studies with human or animal subjects performed by the any of the authors. This review paper complies with the current laws of Australia and the USA. References Armstrong K, Micco E, Carney A, Stopfer J, Putt M (2005) Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA 293(14):1729–1736. doi:10.1001/jama.293.14.1729 Bouchard L, Blancquaert I, Eisinger F, Foulkes WD, Evans G, Sobol H, Julian-Reynier C (2004) Prevention and genetic testing for breast cancer: variations in medical decisions. Soc Sci Med 58(6):1085–1096PubMedCrossRef Selleckchem Fulvestrant Bowen D, Hickman KM, Powers D (1997) Importance of psychological variables in understanding risk perceptions and breast cancer screening of African American women. Womens Health 3(3–4):227–242PubMed Cancer Institute NSW (2013a) Information for people and families with a BRCA2 gene fault (mutation). Cancer Institute NSW. https://www.eviq.org.au/Protocol/tabid/66/categoryid/441/id/765/Information+for+people+and+families+with+a+BRCA2+gene+fault+%28mutation%29.aspx. Accessed 20 Nov 2012 Cancer Institute NSW (2013b) Information for people and families with a faulty BRCA1 gene (mutation). Cancer Institute NSW. https://www.eviq.org.au/Protocol/tabid/66/categoryid/441/id/764/Information+for+people+and+families+with+a+faulty+BRCA1+gene+%28mutation%29.aspx.
Accessed 2 Nov 2012 Charles S, Kessler L, Stopfer JE, Domchek S, Halbert CH (2006) Satisfaction Thymidylate synthase with genetic counseling for BRCA1 and BRCA2 mutations among African American women. Patient Educ Couns 63(1–2):196–204PubMedCrossRef Donovan KA, Tucker DC (2000) Knowledge about genetic risk for breast cancer and perceptions of genetic testing in a sociodemographically diverse sample. J Behav Med 23(1):15–36PubMedCrossRef Durfy SJ, Bowen DJ, McTiernan A, Sporleder J, Burke W (1999) Attitudes and interest in genetic testing for breast and ovarian cancer susceptibility in diverse groups of women in western Washington. Cancer Epidemiol Biomarkers Prev 8(4 Pt 2):369–375PubMed Easton DF, Ford D, Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers.
No related posts.